A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

Study identifier:D7460C00003

ClinicalTrials.gov identifier:NCT05587998

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-blind, Placebo-controlled, Fixed Sequence Study to Assess the Effect on Respiratory Drive of Multiple Doses of AZD4041 When Co-administered With a Single Dose of Morphine in Healthy Recreational Opioid Users

Medical condition

Opioid Use Disorder

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Morphine, AZD4041

Sex

All

Actual Enrollment

45

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 31 Aug 2022
Primary Completion Date: 25 May 2023
Study Completion Date: 25 May 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria